> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Biogennix Gains Expanded Indication for Agilon
- URL: https://www.fdaweb.com/biogennix-gains-expanded-indication-for-agilon/
- Published: 2020-03-04T12:00:00.000Z
- Updated: 2026-09-14T16:05:37.000Z
- Author: David McFarland
- Tags: Devices, #legacy-id-D5146246

FDA has cleared a Biogennix 510(k) for an expanded indication for its Agilon moldable bone grafting product — use in posterolateral spine procedures when mixed with autograft. The device contains a high purity, Type 1 fibrillar bovine collagen, which is intended to provide a site for cell attachment, migration, proliferation, and differentiation, the company says. It also contains the company’s TrelCor technology, a proprietary material engineered to provide the “optimal chemistry and architecture for bone healing,” Biogennix says.